After Denosumab Deals, Alvotech Lines Up Filings

Firm Reports Positive Trial Data For AVT03 Biosimilar To Prolia/Xgeva Ahead Of Submissions

 
• By Dave Wallace

Following positive clinical trial results for its AVT03 proposed denosumab biosimilar to Prolia/Xgeva, Alvotech is planning filings in “major global markets.” Launches are expected to follow through recently-agreed partnerships.

Globe image constructed from data
Alvotech is preparing multiple denosumab filings in “major global markets” • Source: Shutterstock

More from Biosimilars

More from Products